e-learning
resources
ERJ
2013
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Sildenafil: a definitive NO in COPD
Vonk-Noordegraaf Anton, Boerrigter Bart G.
Source:
Eur Respir J 2013; 42: 893-894
Journal Issue:
October
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Vonk-Noordegraaf Anton, Boerrigter Bart G.. Sildenafil: a definitive NO in COPD. Eur Respir J 2013; 42: 893-894
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Inhaled corticosteroids in COPD: the clinical evidence
Source: Eur Respir J 2015; 45: 525-537
Year: 2015
Sildenafil and aerolized iloprost treatment in two cases with primary pulmonary hypertension
Source: Eur Respir J 2005; 26: Suppl. 49, 520s
Year: 2005
Onbrace: A real-life evaluation of indacaterol maintenance treatment for COPD
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Short-acting bronchodilator reversibility does not predict the response to long-term treatment by indacaterol 150 µg in COPD: REVERBREZ study
Source: Annual Congress 2013 –Respiratory and cardiovascular abnormalities in COPD: the role of exercise, nutritional status and inflammation
Year: 2013
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Comparison of indacaterol with tiotropium or once-daily dual long-acting bronchodilator therapy with roflumilast for severe COPD
Source: International Congress 2014 – Markers
Year: 2014
Inhaled corticosteroids: a controversial add-on treatment in COPD
Source: Eur Respir J 2010; 36: 973-974
Year: 2010
Inhaled treatment of COPD: A delphi consensus statement
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016
Inhaled corticosteroids in COPD: a case in favour
Source: Eur Respir J 2009; 34: 10-12
Year: 2009
Eligibility of patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy
Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections
Year: 2015
Patients with severe COPD show significant improvements in dyspnea and lung function with once-daily QVA149: The BLAZE study
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Inhaled corticosteroids in COPD: the case against
Source: Eur Respir J 2009; 34: 13-16
Year: 2009
Beta-blockers and COPD: the show must go on
Source: Eur Respir J 2016; 48: 600-603
Year: 2016
Clinical and inhaled drug profile of COPD patients with indication for beta-blockers who are on beta-blockers
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Inhaled iloprost plus oral sildenafil in patients with pulmonary hypertension
Source: Eur Respir J 2001; 18: Suppl. 33, 324s
Year: 2001
Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE study
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD
Source: Eur Respir J 2009; 33: 1039-1044
Year: 2009
Weaning from inhaled corticosteroids in COPD: the evidence
Source: Eur Respir J 2015; 46: 1232-1235
Year: 2015
Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability
Source: International Congress 2014 – Markers
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept